The present analysis describes the survival outcomes in a large group of patients with localized and metastatic aRMS, prospectively enrolled and uniformly treated in recent CWS trials and registry, in relation to FOXO1 fusion status and fusion type (PAX3 vs. PAX7) in the context of known clinical factors associated with prognosis. This evidence concerns the gene PAX7 and alveolar rhabdomyosarcoma.